Physicians screening more patients for prostate cancer

December 05, 2001

Doctors report increased use of prostate specific antigen tests to screen for early stage prostate cancer, according to a new study. Although increased screening is generally seen as a good thing, in this case, it may not be driven by medical decision-making.

In 1998, primary care physicians reported ordering PSA tests in 81 percent of routine health maintenance exams for men over 50 compared with 73 percent in 1993.

"Our results contrast with other studies that have shown that a primary or important reason for PSA testing was belief that aggressive treatment would reduce mortality or that screening would reduce mortality," say lead authors John D. Voss, M.D., and Joel M. Schectman, M.D., M.P.H., of the department of internal medicine at the University of Virginia Health System in Charlottesville.

Fewer than half the physicians surveyed in 1998 thought that early detection and treatment of prostate cancer would reduce the death rate, according to the study. They were more likely to offer routine screening because they thought that it was a standard of care and because they thought that they would be at risk of malpractice suit if a patient who was not screened later developed prostate cancer.

The results are published in the December issue of the Journal of General Internal Medicine.

Prostate cancer is the second most common cause of death due to cancer in American men. Approximately 200,000 new cases are diagnosed every year.

In 1993, the researchers received responses to their survey from 176 general internists and family practitioners who contracted with a health maintenance organization in metropolitan Washington, D.C. The questionnaire asked the physicians how frequently and why they screened men without symptoms of prostate cancer during routine exams. The researchers then received responses to a second survey from 108 of these 176 physicians in 1998.

Between 1993 and 1998, 43 percent of the physicians reported that they more frequently screened for prostate cancer with a PSA test in patients without symptoms, and 13 percent said they were less likely to order PSA tests.

Two-thirds of the physicians believed that PSA screening should be offered to all men starting at age 50, and 75 percent thought these tests should be given to all men over 40 years old who were at high risk of getting prostate cancer.

Since the PSA test was introduced, physicians have been able to detect prostate cancer before men start to experience symptoms, leading to earlier treatment. However, it is not clear if earlier treatment leads to fewer deaths.

Because of the lack of data proving that PSA screening reduces mortality from prostate cancer, several prominent organizations, including the American College of Physicians, the U.S. Preventive Services Task Force, the American College of Preventive Medicine and the American Academy of Family Practice, do not recommend routine PSA screening or recommend it only as an option after careful discussion of risks and benefits on an individual patient basis.

The American Urologic Association, however, does advocate use of routine PSA screening and the American Cancer Society recommends that physicians offer PSA screening to all men who are at least 50 years old and who have an average risk of developing prostate cancer and have a life expectancy of at least 10 years.

"Prostate cancer is an important health problem that can be diagnosed in a pre-symptomatic stage. However, screening programs are only effective when treatment at the pre-symptomatic stage improves patient mortality or other important outcomes, a point still unsettled in the case of prostate cancer," say Voss and Schectman.

Further research is essential to improve screening and treatment for prostate cancer. "Clinicians need objective guidelines based on clinical data instead of the current contradictory guidelines," they say.
-end-
The Journal of General Internal Medicine, a monthly peer-reviewed journal of the Society of General Internal Medicine, publishes original articles on research and education in primary care. For information about the journal, contact Renee F. Wilson at (410) 955-9868.

Posted by the Center for the Advancement of Health http://www.cfah.org. For more research news and information, go to our special section devoted to health and behavior in the "Peer-Reviewed Journals" area of Eurekalert!, http://www.eurekalert.org/jrnls/cfah/. For information about the Center, call Ira Allen, iallen@cfah.org (202) 387-2829.

Center for Advancing Health

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.